Search Results

You are looking at 1 - 10 of 38 items for :

Clear All
Full access

Olga Frankfurt and Martin S. Tallman

-metHuG-CSF): the first 10 years . Blood 1996 ; 88 : 1907 – 1929 . 2. Spiekermann K Roesler J Emmendoerffer A . Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications . Leukemia 1997

Full access

Dung T. Le and Elizabeth M. Jaffee

) obtained through leukapheresis. Enriched monocytes are incubated with a construct that fuses prostatic acid phosphatase (PAP) with granulocyte-macrophage colony-stimulating factor (GM-CSF). 1 , 2 The PAP serves as the tumor antigen and the GM-CSF targets

Full access

Martha Wadleigh and Richard M. Stone

-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia . J Clin Oncol 1997 ; 15 : 3496 – 3506 . 5 Lowenberg B Suciu S Archimbaud E . Use of recombinant GM-CSF during and after remission induction

Full access

Jacqueline N. Poston and Pamela S. Becker

observed in patients who received granulocyte-macrophage colony-stimulating factor (GM-CSF) between days 4 and 8 of induction chemotherapy compared with a decline in cells in S-phase for those receiving placebo. 5 Enhancing entry into S-phase theoretically

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns and Lenora Pluchino

complications may enhance the cost-effectiveness. These NCCN Guidelines focus on the 2 MGFs that have shown the most promise in terms of clinical use: granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF

Full access

Michelle T. Ashworth and Adil Daud

-stimulating factor (GM-CSF). Five months later, in 2010, PET/CT identified a hypermetabolic 2.2 x 1.5-cm soft tissue nodule in the left paraspinous musculature, and biopsy confirmed metastatic melanoma. A clinical trial with vemurafenib was discussed again. A

Full access

Pamela S. Becker

-macrophage colony-stimulating factor (GM-CSF; approved as sargramostim), and plerixafor. Figure 1 Stem cell mobilization. The hematopoietic stem cell resides in the endosteal niche, interacting with extracellular matrix components such as fibronectin (Fn

Full access

Jeffrey Crawford

Since the initial approval of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) for clinical use in 1991, our understanding of these agents has grown substantially. Laboratory investigation

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer and Maria Ho

-macrophage colony stimulating factor (GM-CSF), is limited to use after induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. It should be noted that recommendations are based on evidence derived mainly from studies on G

Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian and Anita Engh

injections for melanoma. Key results from those showing the most promise are summarized in Table 3 . Talimogene Laherparepvec (T-VEC): Intralesional or perilesional injection of melanoma metastases with granulocyte-macrophage colony-stimulating factor (GM-CSF